Compare IDEXX Laboratories, Inc. (IDXX) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Oklo Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Oklo Inc trades at $34.67 (market cap $6.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.3× Oklo Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 16,238,368). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Oklo Inc for 32 Days on average.
| IDXX | OKLO | |
|---|---|---|
Market Cap | $40.43B | $6.43B |
Volume | 692,164 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $766.68 | $174.14 |
52-Week Low | $504.70 | $34.57 |
Typical Hold Time | 46 Days | 32 Days |
Enterprise Value | $41.32B | $3.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
OKLO trades at $34.70, down 5.76% in the last 24 hours, with a bearish technical signal from moving averages. The company reported no revenue in 2025 and a net loss of $105.66 million, with a negative net income margin of -12,625.54%. Recent news highlights competition in the nuclear sector and a $1 billion stock sale, while analyst consensus remains bullish with a $78.63 price target.
Outlook: High growth potential in the nuclear energy market, supported by a strong buy rating from analysts. Risks include significant cash burn, lack of revenue, and execution challenges in commercializing reactor technology. The stock's upside depends on successful project deployment and future revenue generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
